Atea Pharmaceuticals annual return on equity
2020
2021
2022
2023
2024
2025
Atea Pharmaceuticals Return on Equity (ROE) Growth & History (AVIR)
Atea Pharmaceuticals's return on equity was −44.34% for fiscal 2025.
View full Atea Pharmaceuticals company overviewAtea Pharmaceuticals annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −44.34% | −10.46 pp |
| 2024 | 2024-12-31 | −33.88% | −11.14 pp |
| 2023 | 2023-12-31 | −22.74% | −5.58 pp |
| 2022 | 2022-12-31 | −17.16% | −36.43 pp |
| 2021 | 2021-12-31 | 19.27% | +23.66 pp |
| 2020 | 2020-12-31 | −4.39% | — |
Atea Pharmaceuticals quarterly return on equity
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −15.04% | −5.46 pp |
| Q1 2026 | 2026-03-31 | −17.85% | −9.79 pp |
| Q4 2025 | 2025-12-31 | −15.18% | −7.70 pp |
| Q3 2025 | 2025-09-30 | −12.36% | −5.70 pp |
| Q2 2025 | 2025-06-30 | −9.58% | −1.32 pp |
| Q1 2025 | 2025-03-31 | −8.06% | +3.86 pp |
| Q4 2024 | 2024-12-31 | −7.48% | −0.59 pp |
| Q3 2024 | 2024-09-30 | −6.66% | −1.07 pp |
| Q2 2024 | 2024-06-30 | −8.26% | −3.64 pp |
| Q1 2024 | 2024-03-31 | −11.92% | −6.29 pp |
| Q4 2023 | 2023-12-31 | −6.89% | −1.61 pp |
| Q3 2023 | 2023-09-30 | −5.60% | −4.38 pp |
| Q2 2023 | 2023-06-30 | −4.62% | +0.06 pp |
| Q1 2023 | 2023-03-31 | −5.64% | +0.42 pp |
| Q4 2022 | 2022-12-31 | −5.28% | −23.42 pp |
| Q3 2022 | 2022-09-30 | −1.22% | +3.56 pp |
| Q2 2022 | 2022-06-30 | −4.68% | −4.94 pp |
| Q1 2022 | 2022-03-31 | −6.05% | −11.47 pp |
| Q4 2021 | 2021-12-31 | 18.14% | +9.37 pp |
| Q3 2021 | 2021-09-30 | −4.78% | — |
| Q2 2021 | 2021-06-30 | 0.26% | — |
| Q1 2021 | 2021-03-31 | 5.42% | — |
| Q4 2020 | 2020-12-31 | 8.77% | — |
Atea Pharmaceuticals return on equity trends
Over the last five fiscal years, Atea Pharmaceuticals's return on equity decreased from −4.39% to −44.34%, a change of −39.94 percentage points. The latest reported quarter, Q2 2026, shows −15.04%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Atea Pharmaceuticals source filings ↗